Arvinas LLC

Apr 04, 2018

Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation Platform

Mar 19, 2018

Arvinas to Present at the 17th Annual Needham Healthcare Conference

Feb 09, 2018

Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC® ARV-110 at ASCO 2018 Genitourinary Cancers Symposium

Jan 04, 2018

Arvinas Announces Research Collaboration and License Agreement with Pfizer Inc. for the Discovery and Development of Protein Degradation Drug Candidates

Dec 08, 2017

Arvinas Presents New Data on Oral Estrogen Receptor PROTAC Degrader at 2017 San Antonio Breast Cancer Symposium

Nov 21, 2017

Arvinas and Macroceutics Establish DEL Screening Collaboration on Undruggable Targets

Nov 15, 2017

Arvinas Expands Strategic License Agreement with Genentech

Nov 02, 2017

Arvinas Nominates Oral Clinical Candidate for Androgen Receptor Degrader Program

Sep 20, 2017

Arvinas Appoints Dr. John Houston as President and Chief Executive Officer